Locations:
SearchLDL, or low-density lipoprotein, carries cholesterol throughout the body and can accumulate in artery walls, leading to plaque buildup
New findings by Cleveland Clinic physicians show that the combination of a new drug, obicetrapib with an established medication, ezetimibe, reduced low-density lipoprotein (LDL) cholesterol levels by 48.6% after about three months – producing more effective results than either drug alone.
Findings from the Phase 3 clinical trial were presented today during a late breaking science session at the European Atherosclerosis Society’s annual meeting in Glasglow, Scotland and simultaneously published in The Lancet.
Too much LDL cholesterol (often referred to as the “bad” cholesterol) can lead to atherosclerotic disease - plaque buildup in the walls of arteries - that can increase the risk for a heart attack or stroke. Patients who have established atherosclerotic disease, or who are at high risk of developing it, benefit from the reduction in LDL cholesterol to decrease their risk of adverse events.
“Despite statin therapies and other non-statin medications, many patients with a high risk of heart disease or existing heart disease don't reach their LDL cholesterol targets,” said Ashish Sarraju, M.D., lead author and preventive cardiologist at Cleveland Clinic. “This combination therapy helped high-risk patients who need additional LDL cholesterol lowering to potentially reach their goals.”
Many factors can result in high levels of LDL, such as poor diet, being overweight, smoking and increased age. Other factors, such as genetics, cannot be modified. For some people, lifestyle modifications are beneficial, but for many others, medications are required. Some even require multiple lipid-lowering therapies.
In this multi-center clinical trial, researchers enrolled 407 patients with LDL cholesterol levels greater than 70 mg/dL despite maximal lipid lowering therapy, including statin drugs in nearly all. They were randomized to treatment with the fixed dose combination of obicetrapib-ezetimibe, either therapy alone, or matching placebo. After 84 days of treatment, the fixed-dose therapy lowered LDL cholesterol by 48.6% when compared with placebo. LDL cholesterol was reduced by 31.7% with obicetrapib monotherapy, compared with placebo. All treatments were generally well tolerated.
“These results support the potential of using this fixed dose combination to help treat an often difficult to treat patient population,” said Steven Nissen, M.D., senior author and Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic. “If approved by regulatory authorities, this could allow high-risk patients who need additional LDL cholesterol lowering to potentially reach their targets.”
The trial was funded by NewAmsterdam Pharma.
Dr. Nissen has served as a consultant for many pharmaceutical companies and has overseen clinical trials for Amgen, AbbVie, AstraZeneca, Bristol Myers Squibb, Mineralys, NewAmsterdam Pharma, Eli Lilly and Company, and Novartis. However, he does not accept honoraria, consulting fees or other compensation from commercial entities.
Dr. Sarraju has consulted for several pharmaceutical companies and participated in clinical trials for NewAmsterdam Pharma, Mineralys, and Kardigan, with no personal compensation or honoraria.
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 83,000 employees worldwide are more than 6,600 salaried physicians and researchers, and 21,900 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,725-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 300 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2025, there were 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures throughout Cleveland Clinic’s health system. Visit us at clevelandclinic.org. Follow us at x.com/CleClinicNews. News and resources are available at newsroom.clevelandclinic.org.
Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.
